Karyopharm Therapeutics Balance Sheet - Quarterly (NASDAQ:KPTI)

Add to My Stocks
$18.57 $0.57 (3.17%) KPTI stock closing price Sep 18, 2018 (Closing)

A balance sheet is one of the three key financial statements released by a publicly listed company like Karyopharm Therapeutics, and helps in stock analysis. A balance sheet can help evaluate the financial performance of a company. Ratios like return on total assets and current ratio, which also uses cash on hand can be used to measure the operating efficiency of a firm, and can be used to conduct a more accurate Karyopharm Therapeutics stock analysis. Good quarterly results indicate a company's strong financial performance. Its important to check all financial statements including the balance sheet. The balance sheet shows total liabilities of $43.12M and shareholders equity of $213.47M. Karyopharm Therapeutics revenue and Karyopharm Therapeutics operating cash flow are important in understanding the financial capacity of the company.

View and download Karyopharm Therapeutics quarterly results to get the balance sheet details for the latest 40 quarters data.
show more
Quarterly
Annual
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q1
Cash118.97M37.49M69.19M54.65M55.58M25.77M49.66M43.9M37.71M42.18M
Marketable Securities122.16M93.41M77.47M64.95M88.07M84.3M79.88M82.9M85.01M94.22M
Receivables----------
Inventory----------
Raw Materials----------
Work In Progress----------
Finished Goods----------
Notes Receivable----------
Other Current Assets3.44M2.39M1.75M2.07M2.07M2.14M2.08M3.44M1.46M1.72M
Total Current Assets
244.56M133.31M148.42M121.68M145.72M112.23M131.63M130.25M124.2M138.14M
Property Plant & Equipment5.52M5.18M4.74M4.68M4.68M4.68M4.68M4.65M4.65M4.65M
Accumulated Depreciation2.91M2.72M2.55M2.38M2.2M2.02M1.84M1.66M1.48M1.3M
Net Property Plant & Equipment
2.61M2.45M2.18M2.3M2.47M2.65M2.83M2.99M3.17M3.34M
Investment & Advances8.78M10.31M29.39M39.49M37.26M40.25M45.43M49.59M42.93M50.16M
Other Non-Current Assets----------
Deferred Charges----------
Intangibles----------
Deposits & Other Assets----------
Total Assets
256.59M146.37M180.29M163.77M185.75M155.43M180.38M183.62M170.89M192.13M
Notes Payable----------
Accounts Payable3.79M4.94M5.66M1.89M3.24M4.24M4.75M2.19M4.06M4.1M
Current Portion Long-Term Debt----------
Current Portion Capital Leases----------
Accrued Expenses22.97M21.54M21.44M17.71M12.87M10.74M11.36M12.3M11.11M8.65M
Income Taxes Payable----------
Other Current Liabilities9.78M20.24M22.35M1.55M1.39M-----
Total Current Liabilities
36.54M46.73M49.46M21.15M17.52M15.48M16.47M14.95M15.52M13.22M
Mortgages----------
Deferred Taxes/Income6.57M4.11M1.36M1.44M1.51M1.59M1.66M1.73M1.8M1.87M
Convertible Debt----------
Long-Term Debt----------
Non-Current Capital Leases----------
Other Long-Term Liabilities----------
Total Liabilities
43.12M50.84M50.83M22.59M19.03M17.07M18.14M16.69M17.33M15.09M
Minority Interest----------
Preferred Stock----------
Common Stock Net----------
Capital Surplus781.18M629.61M625.01M597.56M592.53M534.83M528.61M506.12M467.16M460.52M
Retained Earnings-567.45M-533.8M-495.34M-456.3M-425.66M-396.27M-366.1M-339.16M-313.74M-283.58M
Treasury Stock----------
Other Liabilities-0.26M-0.28M-0.21M-0.09M-0.16M-0.2M-0.27M-0.02M--
Shareholders Equity213.47M95.52M129.46M141.17M166.71M138.36M162.24M166.93M153.56M177.03M
Total Liabilities & Shareholders Equity256.59M146.37M180.29M163.77M185.75M155.43M180.38M183.62M170.89M192.13M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

The latest Karyopharm Therapeutics stock price, and Karyopharm Therapeutics historical stock prices show the stock price movement over time, and the Karyopharm Therapeutics PE ratio chart displays the PE ratio movement. Apart from stock price, one should also look at balance sheet items which mainly comprise of the following:

  • Assets: Anything that the Karyopharm Therapeutics company owns and is a part of its books. Assets can be of three types: fixed, current and other assets which includes intangibles, advances. Internet companies typically don't have a lot of assets as there is not much investment in say machinery, equipment etc. Karyopharm Therapeutics had total assets of $256.59M.
  • Liabilities: The total liabilities of Karyopharm Therapeutics for the quarter 2018 Q2 total to $43.12M. Liabilities for a company like Karyopharm Therapeutics include bank loans, services which have been availed for which a settlement in the form of cash/ asset transfer needs to be done in future etc. A firm takes on such obligations to grow its business which in turn will generate future economic benefits for its business.

Karyopharm Therapeutics Balance Sheet - Key Ratios

Current ratio
6.69
Debt to equity ratio
0
Asset turnover ratio
0.4
Receivables turnover
0
Price to book ratio
6.98